Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018078076) A DELIVERY SYSTEM FOR TARGETED DELIVERY OF A THERAPEUTICALLY ACTIVE PAYLOAD
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/078076 International Application No.: PCT/EP2017/077559
Publication Date: 03.05.2018 International Filing Date: 27.10.2017
IPC:
A61K 47/59 (2017.01) ,A61P 35/00 (2006.01)
[IPC code unknown for A61K 47/59]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
TECHNISCHE UNIVERSITÄT DRESDEN [DE/DE]; Helmholtzstrasse 10 01069 Dresden, DE
Inventors:
TEMME, Achim; DE
Agent:
MAIKOWSKI & NINNEMANN, PATENTANWÄLTE, PARTNERSCHAFT MBB; P.O. Box 15 09 20 10671 Berlin, DE
Priority Data:
16196144.628.10.2016EP
Title (EN) A DELIVERY SYSTEM FOR TARGETED DELIVERY OF A THERAPEUTICALLY ACTIVE PAYLOAD
(FR) SYSTÈME D'APPORT DESTINÉ À L'APPORT CIBLÉ D'UNE CHARGE UTILE THÉRAPEUTIQUEMENT ACTIVE
Abstract:
(EN) The present invention provides the modular design and assembly of novel targeting bio-conjugates, exclusively assembled by means of biotin-biotin binding element conjugation, comprising mono-biotinylated cell binding component, a tetrameric biotin-binding element, and mono-biotinylated payload for therapeutic and diagnostic purposes. In addition, there is provided a method of delivering the payload, such as therapeutic oligonucleotides, via mono-biotinylated targeting devices, such as antibodies or ligands, into eukaryotic cells by means of receptor-mediated endocytosis. The targeting bio-conjugates are suitable for use in the areas of medicine, pharmacy and biomedical research.
(FR) La présente invention concerne la conception et l'assemblage modulaires de nouveaux bio-conjugués de ciblage, exclusivement assemblés au moyen d'une conjugaison d'éléments de liaison biotine-biotine, comprenant un composant de liaison cellulaire mono-biotinylé, un élément de liaison de biotine tétramère, ainsi qu'une charge utile mono-biotinylée, à des fins thérapeutiques et diagnostiques. De plus, l'invention concerne un procédé d'apport de la charge utile, telle que des oligonucléotides thérapeutiques, par l'intermédiaire de dispositifs de ciblage mono-biotinylés, tels que des anticorps ou des ligands, dans des cellules eucaryotes au moyen d'une endocytose induite par un récepteur. Ces bio-conjugués de ciblage sont appropriés à une utilisation dans le domaine de la médecine, de la pharmacie et de la recherche biomédicale.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)